Research & Development (R&D) jobs are the most in-demand across the Life Sciences sector with vacancies up 5% year-on-year. That’s according to new research from the Association of Professional Staffing Companies (APSCo), the trade association for the professional staffing sector.
At work, less than 18% of people use a time management system, and 1 in 8 never feel in control of their work. With the Life Science industry demanding more from recruiters and hiring managers every day, now is the time to review how your time is currently being spent, and implement new techniques to help you stay productive and motivated at work.
Bagsværd, Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities.
RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion.
Research by Pharmaceutical Technology found that in the 2021-2022 reporting year, 95.7% of pharmaceutical companies with a headcount above 250 pay their male employees higher than their female employees. The same research found that across the pharmaceutical industry, median hourly pay was 10% higher for males than females, placing the industry below the UK average of 11.6%.
New Integrated Clinical Site Organization Led by World-Class Clinical Development Experts
London, U.K., 17 November 2022: Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces its expansion into the U.K. with the acquisition of multi-site company Egin Research.
Growth in UK cell and gene therapy manufacturing capacity and employment continues
AMSTERDAM--(BUSINESS WIRE)--Today, Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”) officially launches its commercial-stage enterprise, seeking to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical originators. Avanzanite, a fully authorized distributor of medicinal products, partners with these biopharmaceutical collaborators through flexible, bespoke licensing and distribution partnerships across Europe. The Company’s novel business model enables the global commercialization of promising medicines and addresses the unsustainable inequities in access to innovative orphan drugs across Europe.
As the life science industry continues to embrace more flexible ways of working, you may find yourself managing a team of hybrid or remote workers. As hybrid and remote working come with their own set of both challenges and opportunities, these ways of working also require a very different managerial approach.
